Multiple sclerosis (MS) is widely considered an autoimmune disease, though technically it carries a slightly different label: immune-mediated disease. The distinction is narrow but worth understanding. In a classic autoimmune disease, researchers have pinpointed the exact target (called an antigen) that the immune system attacks. In MS, the immune system clearly attacks the protective coating around nerve fibers in the brain and spinal cord, but the specific antigen that triggers this attack hasn’t been identified yet. Despite that gap, most experts treat MS as autoimmune in nature, and it behaves like one in virtually every practical sense.
What “Immune-Mediated” Actually Means
An immune-mediated disease is one where an abnormal immune response causes the body to attack its own tissues, creating inflammation and damage. MS fits squarely in that definition. The immune system targets myelin, the insulating layer that wraps around nerve fibers and allows electrical signals to travel quickly through the nervous system. When myelin is damaged, signals slow down, get distorted, or stop altogether. That’s what produces the wide range of MS symptoms, from numbness and vision problems to difficulty walking.
The reason MS hasn’t been formally reclassified as a straightforward autoimmune disease comes down to one missing piece: no one has yet identified the precise molecule on myelin that first provokes the immune system into action. In conditions like type 1 diabetes, that trigger molecule is known. In MS, we know the damage is immune-driven and we know where it happens, but the initial spark remains unclear. For patients, this distinction has little practical impact. Treatments target the immune system, and the disease is managed as an autoimmune condition.
How the Immune System Attacks the Brain
The brain and spinal cord are normally shielded from immune activity by the blood-brain barrier, a layer of tightly connected cells lining the blood vessels in the central nervous system. These cells are packed together without gaps, preventing most immune cells and large molecules from crossing into brain tissue. In MS, this barrier is breached.
The process starts with certain white blood cells (T-cells) that become activated in the bloodstream. Everyone carries T-cells capable of recognizing myelin proteins, but in healthy people, these cells remain dormant. In MS, something activates them. One leading theory is that infections, particularly viral infections, can wake up these myelin-reactive T-cells through a case of mistaken identity: the immune cells confuse a viral protein with a myelin protein.
Once activated, these T-cells latch onto the walls of blood vessels in the brain using sticky surface molecules called integrins. They then squeeze between the tightly joined cells of the blood-brain barrier, a process researchers describe as literally “walking through” it. After crossing, they still need to break through a layer of structural proteins surrounding the blood vessel, using enzymes that dissolve this outer barrier like a chemical key. Once inside the brain’s white matter, the immune cells launch an inflammatory attack on the myelin sheath, creating the lesions visible on MRI scans.
The Epstein-Barr Virus Connection
One of the strongest environmental risk factors for MS is prior infection with the Epstein-Barr virus (EBV), the common virus that causes mononucleosis. A large study tracking over 10 million military service members found that people infected with EBV were 32 times more likely to develop MS than those who were never infected. That’s a striking number, and it has reshaped how researchers think about what initiates the disease.
Nearly 95% of adults worldwide have been infected with EBV at some point, which means infection alone isn’t enough to cause MS. But among people who develop MS, prior EBV infection is almost universal. The leading explanation is that EBV may alter the immune system in a way that makes it more likely to mistakenly attack myelin, particularly in people who are already genetically susceptible.
Genetic Risk Factors
MS is not directly inherited, but genetics play a significant role in susceptibility. The strongest known genetic link involves a set of immune system genes called HLA genes, which help the body distinguish its own proteins from foreign invaders. Carrying specific variants of these genes can nearly triple the risk. One variant, HLA-DRB1*15, raises the odds of developing MS by about 2.8 times. Another variant, HLA-DRB1*03, increases risk by roughly 1.8 times.
Interestingly, other variants of the same gene appear to be protective. People carrying HLA-DRB1*01 or HLA-DRB1*11 have roughly half the typical risk of developing MS. This suggests the disease isn’t just about having “bad” genes but about the balance of risk and protective factors in a person’s immune blueprint.
How Many People Are Affected
About 2.9 million people worldwide live with MS, a number that has risen from 2.3 million in 2013. Some of that increase reflects better diagnosis and reporting, but it also appears that MS is genuinely becoming more common in certain populations. The disease is two to three times more common in women than men, and it occurs most frequently in regions farther from the equator, which has led researchers to investigate the role of vitamin D and sunlight exposure.
Types of MS and How They Differ
MS doesn’t follow the same course in everyone. About 85% of people are initially diagnosed with relapsing-remitting MS (RRMS), which involves clearly defined episodes of new or worsening symptoms (relapses) followed by periods of partial or complete recovery. Between relapses, the disease may appear stable for months or even years. Over time, many people with RRMS eventually transition to a progressive phase where disability accumulates more steadily.
The remaining 15% are diagnosed with primary progressive MS (PPMS), where neurological function worsens from the very start without distinct relapses or remissions. PPMS can have brief periods of stability, but the overall trajectory is one of gradual decline. This form tends to be diagnosed later in life and affects men and women more equally than relapsing forms.
How Diagnosis Works
Diagnosing MS requires showing that damage has occurred in at least two different areas of the central nervous system at two different points in time. Doctors call these requirements “dissemination in space” and “dissemination in time.” MRI scans are the primary tool for meeting both criteria, as they can reveal characteristic lesions in the brain and spinal cord. Updated diagnostic guidelines also allow the presence of specific proteins in spinal fluid (oligoclonal bands) to help confirm a diagnosis earlier, sometimes after a single clinical episode, if MRI findings already show damage in multiple locations.
How Treatments Target the Immune System
The fact that MS treatments work by suppressing or redirecting the immune system is itself strong evidence that the disease is autoimmune in nature. Modern disease-modifying therapies take several different approaches to interrupting the immune attack on myelin.
One class of treatments depletes specific immune cells called B-cells, which play a role in driving inflammation and presenting myelin fragments to other immune cells. These therapies target a protein on the surface of B-cells and essentially remove them from circulation, reducing the immune system’s ability to sustain attacks on myelin.
Another approach traps immune cells inside lymph nodes so they never reach the brain. These medications block a chemical signaling pathway that immune cells rely on to exit lymph nodes and enter the bloodstream. With fewer immune cells circulating, fewer can cross the blood-brain barrier and cause damage. Some newer versions of these drugs can also cross into the brain directly, where they may help protect nerve cells and promote repair of damaged myelin.
None of these treatments cure MS, but they can significantly reduce the frequency and severity of relapses, slow disability progression, and in some cases reduce the number of new lesions appearing on MRI. Early and consistent treatment generally leads to better long-term outcomes, particularly for people with relapsing forms of the disease. Treatment options for primary progressive MS are more limited, though one B-cell-depleting therapy was the first to receive approval specifically for that form.